External comparator studies and the joint application of the estimand and target trial emulation frameworks
The estimand framework (EF) and the target trial emulation framework (TTEF) are two important frameworks that can inform the design and analysis of external comparator (EC) studies. The EF helps clarifying the quantity to be estimated (the "estimand"), especially regarding the handling of...
Saved in:
Main Authors: | , |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_a0c9a3839e4d42c7845aa6a26f016235 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Gerd Rippin |e author |
700 | 1 | 0 | |a Héctor Sanz |e author |
245 | 0 | 0 | |a External comparator studies and the joint application of the estimand and target trial emulation frameworks |
260 | |b Frontiers Media S.A., |c 2024-10-01T00:00:00Z. | ||
500 | |a 2674-0869 | ||
500 | |a 10.3389/fdsfr.2024.1409102 | ||
520 | |a The estimand framework (EF) and the target trial emulation framework (TTEF) are two important frameworks that can inform the design and analysis of external comparator (EC) studies. The EF helps clarifying the quantity to be estimated (the "estimand"), especially regarding the handling of post-baseline intercurrent events which interfere with the existence or interpretation of endpoints. Similarly, the TTEF is instrumental for specifying key design components of a hypothetical randomized trial and identifying which of these an EC study can and cannot emulate. We offer considerations about the joint application of both frameworks by combining the five EF attributes- treatment, population, endpoint, intercurrent events, and population-level summary-with the seven TTEF components- eligibility criteria, treatment strategies, assignment procedures, follow-up period, outcomes, causal contrasts, and data analysis plan. Any overlap is identified, as well as omissions and unique contributions from both frameworks. Furthermore, we highlight specific considerations when applying these joint elements to EC studies. | ||
546 | |a EN | ||
690 | |a external comparator studies | ||
690 | |a external control arm studies | ||
690 | |a externally controlled trials | ||
690 | |a historical control studies | ||
690 | |a estimands | ||
690 | |a target trial emulation | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Frontiers in Drug Safety and Regulation, Vol 4 (2024) | |
787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fdsfr.2024.1409102/full | |
787 | 0 | |n https://doaj.org/toc/2674-0869 | |
856 | 4 | 1 | |u https://doaj.org/article/a0c9a3839e4d42c7845aa6a26f016235 |z Connect to this object online. |